Approximately 200,000 cancer patients are diagnosed with brain metastases each year, yet few treatment options exist because the mechanisms that allow cancer to spread to the brain remain unclear. However, a study recently ...
Dec 8, 2020
0
44
In a comprehensive analysis of patients with cancer who had exceptional responses to therapy, researchers have identified molecular changes in the patients' tumors that may explain some of the exceptional responses. The results ...
Nov 19, 2020
0
28
Through large-scale profiling of protein changes in response to drug treatments in cancer cell lines, researchers at The University of Texas MD Anderson Cancer Center have generated a valuable resource to aid in predicting ...
Nov 5, 2020
0
20
Only 4 percent of all cancer therapeutic drugs under development earn final approval by the U.S. Food and Drug Administration (FDA).
Oct 22, 2020
0
13
The COVID-19 pandemic has impacted virtually every aspect of cancer care and research- from introducing new risks for cancer patients to disrupting the delivery of cancer treatment and the continuity of cancer research, a ...
Oct 6, 2020
0
2
Imaging techniques could replace the need for invasive tissue biopsies in helping rapidly determine whether cancer treatments are working effectively, according to researchers at the University of Cambridge.
Oct 6, 2020
0
6
A new data analysis tool developed by researchers at The University of Texas MD Anderson Cancer Center incorporates a user-friendly, natural-language interface to allow biomedical researchers without specialized expertise ...
Sep 24, 2020
0
28
Higher viral loads are associated with a greater risk of death among cancer and non-cancer patients hospitalized with coronavirus disease 2019 (COVID-19), researchers report September 15 in the journal Cancer Cell. Among ...
Sep 16, 2020
0
4
A new study by researchers at the UCLA Jonsson Comprehensive Cancer Center sheds light on how interferon-gamma (IFN-y), an immune response-stimulating signaling molecule that helps activate immune cells, guides the treatment ...
Sep 10, 2020
0
98
Results from a Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center suggest that a combination of ipilimumab (anti-CTLA-4) plus nivolumab (anti-PD-1) can generate durable responses in a subset ...
Sep 10, 2020
0
62
